Evidence map›Paper›PMID 25261237›Full record

ArticleCancer research2014

In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.

Ethan R Balkin, Aimee Kenoyer, Johnnie J Orozco, Alexandra Hernandez, Mazyar Shadman, Darrell R Fisher, Damian J Green, Mark D Hylarides, Oliver W Press, D Scott Wilbur and 1 more

Abstract read
In one paragraph

Article in Cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Optical (Cherenkov) dosimetry to unravel the radiobiological effects of radioisotope based therapy.European journal of nuclear medicine and molecular imaging · 2025
    Article
  2. Article
  3. Cerenkov luminescence and PET imaging ofPhysics in medicine and biology · 2020
    Article
  4. Removal of random-valued impulse noise from Cerenkov luminescence images.Medical & biological engineering & computing · 2020
    Article
  5. 3D-printed Wash Station with Integrated Anesthesia Delivery Manifold for High-throughput Depilation of Laboratory Mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2019
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ethan R BalkinRadiation Oncology, University of Washington, Seattle, Washington.
Aimee KenoyerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Johnnie J OrozcoClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Hematology Division, University of Washington, Seattle, Washington.
Alexandra HernandezClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Mazyar ShadmanClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Medical Oncology, University of Washington, Seattle, Washington.
Darrell R FisherPacific Northwest National Laboratory, Richland, Washington.
Damian J GreenClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Medical Oncology, University of Washington, Seattle, Washington.
Mark D HylaridesClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Oliver W PressClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Medical Oncology, University of Washington, Seattle, Washington.
D Scott WilburRadiation Oncology, University of Washington, Seattle, Washington.
John M PagelClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Medical Oncology, University of Washington, Seattle, Washington. jpagel@fhcrc.org.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
TREATMENT OF B-CELL LYMPHOMAP01CA044991 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PRESS, OLIVER W. · 1988 to 2015
$29.3M
CD45 Pretargeted Radioimmunotherapy for AMLR01CA109663 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PRESS, OLIVER W. · 2004 to 2013
$2.9M
Bone Marrow Transplantation for Hematologic Malignancies using Novel RadioimmunotR01CA138720 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PRESS, OLIVER W. · 2010 to 2014
$1.9M
CD38 Pretargeted Radioimmunotherapy for MyelomaR01CA154897 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GREEN, DAMIAN J. · 2011 to 2015
$1.8M
Bispecific Antibody Engineering for AML RITR01CA136639 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PRESS, OLIVER W. · 2009 to 2013
$1.6M
NCI NIH HHS P01 CA044991NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA109663NCI NIH HHS R01 CA136639NCI NIH HHS R01 CA138720NCI NIH HHS R01 CA154897
6 · The paper itself

Abstract

Cerenkov radiation generated by positron-emitting radionuclides can be exploited for a molecular imaging technique known as Cerenkov luminescence imaging (CLI). Data have been limited, however, on the use of medium- to high-energy β-emitting radionuclides of interest for cancer imaging and treatment. We assessed the use of CLI as an adjunct to determine localization of radioimmunoconjugates to hematolymphoid tissues. Radiolabeled (177)Lu- or (90)Y-anti-CD45 antibody (Ab; DOTA-30F11) was administered by tail vein injection to athymic mice bearing disseminated murine myeloid leukemia, with CLI images acquired at times afterward. Gamma counting of individual organs showed preferential uptake in CD45(+) tissues with significant retention of radiolabeled Ab in sites of leukemia (spleen and bone marrow). This result was confirmed in CLI images with 1.35 × 10(5) ± 2.2 × 10(4) p/s/cm(2)/sr and 3.45 × 10(3) ± 7.0 × 10(2) p/s/cm(2)/sr for (90)Y-DOTA-30F11 and (177)Lu-DOTA-30F11, respectively, compared with undetectable signal for both radionuclides using the nonbinding control Ab. Results showed that CLI allows for in vivo visualization of localized β-emissions. Pixel intensity variability resulted from differences in absorbed doses of the associated energies of the β-emitting radionuclide. Overall, our findings offer a preclinical proof of concept for the use of CLI techniques in tandem with currently available clinical diagnostic tools.

Indexed as

ImmunoconjugatesRadiopharmaceuticalsYttrium RadioisotopesAnimalsCell Line, TumorFemaleLeukemiaLuminescent MeasurementsLutetiumMicePhantoms, ImagingRadionuclide ImagingSpleenTissue DistributionImmunoconjugatesLutetiumRadiopharmaceuticalsYttrium Radioisotopes

Identifiers

PMID25261237
PMCPMC4199906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.